Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials.
Richard S NicholasErika HanJoel RaffelJeremy ChatawayTim FriedePublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2018)
Over three decades, PMS trial populations changed and are now older, with a longer disease duration and more disability, with lower on-trial progression rates.